Rheumatology Section, Hospital Universitari Germans Trias i Pujol, Ctra del Canyet s/n, 08916 Badalona, Spain.
Joint Bone Spine. 2010 Mar;77(2):102-7. doi: 10.1016/j.jbspin.2009.10.011. Epub 2009 Dec 31.
The interleukin 1 family is composed by the interleukin 1 (IL-1) and its natural occurring inhibitor, the interleukin 1 receptor antagonist (IL-1Ra). The role of both molecules in rheumatoid arthritis has been widely established, and in this sense new molecules blocking IL-1 actions are under investigation. Anakinra is the recombinant form of IL-1Ra, and has proven to be well tolerated and indicated in the treatment of rheumatoid arthritis. Nevertheless, other molecules such as mAb anti-IL-1 and IL-1 Trap are being developed. Moreover, the recent relation of IL-1 in the inflammasome and pathways of innate immunity has lead to new indications of anti-IL-1 molecules, especially in the autoinflammatory syndromes as well as in other inflammatory diseases. Herein we have performed a review of the literature, limited to English language journals (PUBMED search: combination of descriptors IL-1 and anakinra, systemic juvenile idiopathic arthritis, adult's onset Still's disease, autoinflammatory syndromes, gout, pseudogout, ankylosing spondylitis, and systemic lupus erythematosus from January 1985-December 2008) emphasizing the possible new indications. Although sufficient data is not yet available to fully assess the efficacy and safety of anti-IL-1 molecules in patients with inflammatory disorders other than rheumatoid arthritis, new data is promising.
白细胞介素 1 家族由白细胞介素 1（IL-1）及其天然存在的抑制剂白细胞介素 1 受体拮抗剂（IL-1Ra）组成。这两种分子在类风湿关节炎中的作用已得到广泛证实，在这种情况下，新的阻断 IL-1 作用的分子正在被研究中。阿那白滞素是 IL-1Ra 的重组形式，已被证明具有良好的耐受性，并适用于类风湿关节炎的治疗。然而，其他分子，如 mAb 抗 IL-1 和 IL-1 陷阱，也正在开发中。此外，IL-1 在炎症小体和先天免疫途径中的最新关系导致了抗 IL-1 分子的新适应症，特别是在自身炎症性疾病以及其他炎症性疾病中。在此，我们对文献进行了综述，仅限于英语期刊（PUBMED 搜索：IL-1 和阿那白滞素、全身幼年特发性关节炎、成人发病Still 病、自身炎症性综合征、痛风、假性痛风、强直性脊柱炎和系统性红斑狼疮的描述符组合，从 1985 年 1 月至 2008 年 12 月），强调可能的新适应症。尽管目前还没有足够的数据来充分评估抗 IL-1 分子在除类风湿关节炎以外的炎症性疾病患者中的疗效和安全性，但新的数据是有希望的。
